Geode Capital Management, LLC Prothena Corp Public LTD CO Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

A detailed history of Geode Capital Management, LLC transactions in Prothena Corp Public LTD CO stock. As of the latest transaction made, Geode Capital Management, LLC holds 963,479 shares of PRTA stock, worth $13.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
963,479
Previous 994,278 3.1%
Holding current value
$13.9 Million
Previous $20.5 Million 21.45%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$16.73 - $24.79 $515,267 - $763,507
-30,799 Reduced 3.1%
963,479 $16.1 Million
Q2 2024

Aug 09, 2024
BUY
$19.54 - $26.15 $1.36 Million - $1.82 Million
69,698 Added 7.54%
994,278 $20.5 Million
Q1 2024

May 13, 2024
BUY
$24.75 - $40.66 $481,511 - $791,040
19,455 Added 2.15%
924,580 $22.9 Million
Q4 2023

Feb 13, 2024
BUY
$32.31 - $52.32 $1.49 Million - $2.41 Million
46,065 Added 5.36%
905,125 $32.9 Million
Q3 2023

Nov 13, 2023
BUY
$47.3 - $70.6 $976,224 - $1.46 Million
20,639 Added 2.46%
859,060 $41.4 Million
Q2 2023

Aug 11, 2023
BUY
$48.26 - $78.59 $2.83 Million - $4.61 Million
58,597 Added 7.51%
838,421 $57.2 Million
Q1 2023

May 15, 2023
BUY
$46.97 - $58.27 $3.02 Million - $3.74 Million
64,223 Added 8.97%
779,824 $37.8 Million
Q4 2022

Feb 13, 2023
BUY
$52.05 - $65.0 $4.16 Million - $5.19 Million
79,877 Added 12.56%
715,601 $43.1 Million
Q3 2022

Nov 14, 2022
BUY
$25.16 - $60.63 $101,747 - $245,187
4,044 Added 0.64%
635,724 $38.5 Million
Q2 2022

Aug 12, 2022
SELL
$22.73 - $39.98 $461,305 - $811,394
-20,295 Reduced 3.11%
631,680 $17.2 Million
Q1 2022

May 13, 2022
BUY
$30.27 - $49.22 $859,698 - $1.4 Million
28,401 Added 4.55%
651,975 $23.8 Million
Q4 2021

Feb 11, 2022
BUY
$42.11 - $73.26 $143,216 - $249,157
3,401 Added 0.55%
623,574 $30.8 Million
Q3 2021

Nov 12, 2021
BUY
$48.2 - $78.89 $2.74 Million - $4.48 Million
56,817 Added 10.09%
620,173 $44.2 Million
Q2 2021

Aug 13, 2021
BUY
$21.63 - $57.65 $1.55 Million - $4.14 Million
71,775 Added 14.6%
563,356 $29 Million
Q1 2021

May 12, 2021
BUY
$11.0 - $28.24 $307,934 - $790,550
27,994 Added 6.04%
491,581 $12.3 Million
Q4 2020

Feb 12, 2021
SELL
$10.12 - $13.94 $52,128 - $71,804
-5,151 Reduced 1.1%
463,587 $5.57 Million
Q3 2020

Nov 13, 2020
SELL
$9.93 - $13.47 $796,187 - $1.08 Million
-80,180 Reduced 14.61%
468,738 $4.68 Million
Q2 2020

Aug 13, 2020
SELL
$9.56 - $12.51 $393,948 - $515,512
-41,208 Reduced 6.98%
548,918 $5.74 Million
Q1 2020

May 14, 2020
BUY
$7.54 - $15.77 $156,764 - $327,874
20,791 Added 3.65%
590,126 $6.31 Million
Q4 2019

Feb 13, 2020
BUY
$7.48 - $17.01 $282,497 - $642,416
37,767 Added 7.1%
569,335 $9.01 Million
Q3 2019

Nov 12, 2019
SELL
$6.89 - $10.45 $314,507 - $477,011
-45,647 Reduced 7.91%
531,568 $4.17 Million
Q2 2019

Aug 14, 2019
BUY
$8.85 - $12.49 $276,934 - $390,837
31,292 Added 5.73%
577,215 $6.1 Million
Q1 2019

May 14, 2019
BUY
$10.32 - $14.49 $548,146 - $769,636
53,115 Added 10.78%
545,923 $6.62 Million
Q4 2018

Feb 13, 2019
BUY
$8.73 - $13.74 $436,098 - $686,367
49,954 Added 11.28%
492,808 $5.08 Million
Q2 2018

Aug 14, 2018
BUY
$10.99 - $44.21 $983,901 - $3.96 Million
89,527 Added 25.34%
442,854 $6.46 Million
Q1 2018

May 15, 2018
BUY
$27.95 - $45.04 $224,075 - $361,085
8,017 Added 2.32%
353,327 $13 Million
Q4 2017

Feb 13, 2018
SELL
$35.44 - $63.76 $223,378 - $401,879
-6,303 Reduced 1.79%
345,310 $12.9 Million
Q3 2017

Nov 14, 2017
BUY
$53.83 - $67.75 $697,798 - $878,243
12,963 Added 3.83%
351,613 $22.8 Million
Q2 2017

Aug 14, 2017
BUY
N/A
338,650
338,650 $18.3 Million

Others Institutions Holding PRTA

# of Institutions
184
Shares Held
42.7M
Call Options Held
162K
Put Options Held
102K
View Full List

About PROTHENA CORP PUBLIC LTD CO

PRTA Quotes by TradingView
  • Ticker PRTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,922,800
  • Market Cap $676M
  • Description
  • Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...
More about PRTA
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email